I think it depends on the underlying mutation? Is this high yield?
Seems like a good change, but we should mention osimertinib in another card regarding erlotinib and EGFR inhibition because it isn’t mentioned anywhere else in the deck. Just for context, FA23 does not list osimertinib in their list of EGFR small molecule inhibitors (pg447)
I believe that recent studies have showed superiority of osemirtinib, but neither AMBOSS or UW directly tests on this. UW explanations often use the example of erlotinib for EGFR drugs, AMBOSS does not highlight osemirtinib as “key exam info” - I would leave this as is unless we see it being tested on
1 Like